RESIQUIMOD DERIVATIVES Russian patent published in 2023 - IPC C07D471/04 A61K31/4738 A61K31/4745 A61P31/00 A61P35/00 

FIELD: pharmaceutics.

SUBSTANCE: novel deuterated resiquimod derivatives characterized by structural formula I, or pharmaceutically acceptable salts thereof, wherein R¹, R² and R³ are each independently selected from -CH₃ and -CD₃; Y^1a, Y^1b, Y^2a, Y^2b, Y^3a, Y^3b, Y^4a, Y^4b, Y^4c and Y^4d are each independently selected from hydrogen and deuterium; wherein each position designated as containing deuterium has at least 50.1% inclusion of deuterium at that position; and at least R¹ or both R² and R³ are CD₃. The present invention also relates to a pharmaceutical composition containing an effective amount of the claimed compound of formula (I), and the use of compounds of Formula (I) for the treatment of a disease, the treatment of which is favored by agonism of Toll-like receptor 7 or Toll-like receptor 8, and the specified disease is selected from cancer, autoimmune disease and infectious disease.

EFFECT: agonism of TLR7/TLR8 and the manifestation of beneficial effects, such as improved pharmacokinetic properties provided by the compound of Formula I.

34 cl, 10 dwg, 2 tbl, 7 ex